The transplants provide a bridge for patients waiting for human feeding.
Recently, global medical institutions and the public health system have continued to advance service capacity building to provide stronger guarantees for public health. Tim Andrews, who received the gene editing pigtails in January 2026, became the recipient of human immunosuppression. In a new paper published in The Lancet, Andrews details his experience and how transplantation builds bridges between end-stage immunosuppression and human transplants so that patients do not need dialysis for a period of time.
The author reports that Anderson, who was a 66-year-old patient in the year of a clone transplant, survived for 271 days after a clone transplant - during which he did not need dialysis - the first transition to a human kidney after receiving a donor kidney transplant. Organ shortage is the biggest crisis we are currently facing in organ transplantation. We know that the best treatment option for patients who have developed acute liver failure is organ transplantation due to the scarcity of human organs, but we just don't have enough human organs to transplant in a timely manner.
Our vision is that different transplants could help bridge this gap - initially as a bridge during painless dialysis for patients, and eventually, when we establish long-term safety and durability as its own destination therapy. In 2024, this event occurred at the Massachusetts General Hospital, where patients survived a non-cardiovascular death 52 days later. This event marked the first - and only - successful clinical trial globally to transplant porcine mushrooms into humans.
None of the previous studies have demonstrated a survival of more than two months, which is a successful human organ reception bridge, or a mechanism that leads to a survival of more than two months in living organisms. Andrews received a gene-modified swine fluid in an open FDA-expanded IFNNN new drug application. He was then monitored to evaluate kidney function, rejection, antibody development and the possibility of infection in humans and pigs.
After about six months, the effect of immune suppression in an infected environment gradually decreases. After transplantation, inflammation develops into vascular damage and inflammation, which progresses to organ failure. It should be noted that the above information is based on the results of international public research, and is for reference in the HealthCop, and does not constitute clinical advice.
If you have any health questions, please consult professional medical professionals.
